Max Masucci
Stock Analyst at TD Cowen
(0.20)
# 4,437
Out of 5,114 analysts
22
Total ratings
16.67%
Success rate
-30.77%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $46.48 | +54.91% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $25.07 | -0.28% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $99.74 | -46.86% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $74.95 | +26.75% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $6.59 | +173.14% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $6.69 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $2.95 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $1.94 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $1.50 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $4.95 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.15 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.65 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $134.78 | +248.72% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $6.43 | +288.80% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $101.82 | +42.41% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $46.48
Upside: +54.91%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $25.07
Upside: -0.28%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $99.74
Upside: -46.86%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $74.95
Upside: +26.75%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $6.59
Upside: +173.14%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $6.69
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.95
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.94
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.50
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.95
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.15
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.65
Upside: -
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $134.78
Upside: +248.72%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $6.43
Upside: +288.80%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $101.82
Upside: +42.41%